Gilead Sciences, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.gilead.com

Earnings Score
Moat Score
Safety Score

Market Cap $122.10B
PE 254
Debt $28.53B
Cash $9.99B
EV $140.63B
FCF $10.31B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$480.00M
EBIT	$1.66B
ROE	2%
ROA	3%
FCF	$10.31B
Equity	$19.33B
Growth Stability	2%
PE	254.37
PEG	-19.08
PB	6.32
P/FCF	11.85
P/S	4.25
Price/Cash	0.08
Debt/Equity	1.48
Debt/FCF	2.77
Net Margins	2%
Gross Margins	78%
Op. Margins	6%
Earnings CAGR	-23%
Sales Growth YoY	6%
Sales Growth QoQ	0%
Sales CAGR	0%
FCF CAGR	-5%
Equity CAGR	1%
Earnings Stability	0.26
Earnings Growth YoY	26%
Earnings Growth QoQ	42%
Earnings CAGR 5Y	-13%

Sales CAGR 5Y	4%
FCF CAGR 5Y	-0%
Equity CAGR 5Y	0%
Earnings CAGR 3Y	1%
Sales CAGR 3Y	1%
FCF CAGR 3Y	-3%
Equity CAGR 3Y	-4%
Market Cap	$122.10B
Revenue	$28.75B
Dividend Yield	3%
Payout Ratio	816%
Assets	$59.00B
Total Debt	$28.53B
Cash	$9.99B
Shares Outstanding	1.25B
EV	140.63B
Earnings Score	4%
Moat Score	36%
Safety Score	58%
Final Score	32%
Working Capital	7.17B
Current Ratio	1.6
Gross Profit	$22.50B
Shares Growth 3y	-0%
Equity Growth QoQ	5%
Equity Growth YoY	-15%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

SEC Filings

Direct access to Gilead Sciences, Inc. (GILD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Gilead Sciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Gilead Sciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -23%

Stability 26%

loading chart...

Gilead Sciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Gilead Sciences, Inc..

Years

Calculation mode

= $72B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$10B	$9.7B	$9.2B	$8.7B	$8.2B	$7.8B	$7.4B	$7B	$6.6B	$6.2B	$5.9B	$59B
DCF		$8.9B	$7.6B	$6.5B	$5.6B	$4.8B	$4.2B	$3.6B	$3.1B	$2.6B	$2.3B	$23B
Value	$72B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	55%	44%	18%	25%	24%	0%	23%	17%	21%	2%	2%
ROA	-	32%	21%	14%	10%	6%	15%	12%	12%	3%	3%
ROE	-	70%	23%	25%	24%	0%	29%	21%	25%	2%	2%

Bad Net Margins (1.67%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	1.65	3.21	4.02	3.26	4.54	2.61	3.3	3.61	2.77	2.77
Debt over Equity	1.21	1.36	1.77	1.4	1.2	1.87	1.34	1.29	1.17	1.48	1.48
Growth Stability	-	-	-	45%	68%	2%	100%	100%	100%	9%	2%

Neutral Debt/FCF ratio (2.77)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (1.48)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (2%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-7%	-14%	-15%	1%	10%	11%	-0%	-1%	6%	4%
Earnings YoY growth	-	-26%	-66%	18%	-2%	-98%	7K%	-26%	23%	-91%	-13%
Equity YoY growth	-	1%	6%	5%	5%	-20%	16%	1%	7%	-15%	0%
FCF YoY growth	-	-19%	-29%	-34%	11%	-10%	44%	-23%	-11%	39%	-0%